Given the environment, and with a desire to avoid any unnecessary pressure on HCPs, IQVIA was very careful to not send reminders asking HCPs to complete the survey.
And what, in the view of oncology specialists themselves, this pattern could be 1-2 years down the line assuming COVID-19 no longer existsįirstly, a very short 3-minute survey issued was hosted on our IQVIA’s internal and secure online community of healthcare professionals (HCPs) called DOCNET. The communication channels pharma companies are using to communicate with oncology specialists:. Initiatives Pharma companies can provide oncology specialists to help them deliver the best care possible to their patients, now and in the “new normal”. The current changes anticipated to treatment practices now that restrictions are being relaxed in some areas of the world. 
The specific types of cancer treatment practices are being impacted as a result of COVID-19. 
The number of remote consultations conducted during different phases of the pandemic. The impact on cancer patient visits at different phases of the COVID -19 crisis: are oncologists seeing fewer cancer patients now compared to pre-COVID-19?. Specifically, we wanted to dig deeper and to understand: And so, with lockdown measures restricting the movement and likely identification of patients, and healthcare systems being overwhelmed, we felt it critical to gather feedback from oncology specialists to understand from them directly what impact the pandemic is having on the treatment of cancer. Furthermore, oncology medicines and innovations are a significant market driver. Here we discuss the impact on the oncologist community, not just across the EU5 countries but across the globe, and the extent to which they have had to re-organize oncological care in a matter of weeks.Ĭancer patients are amongst the most vulnerable populations, with or without COVID-19, and early, proactive detection has been a hallmark of treatment paradigms for the past few decades. But looking deeper, at the unique effects the pandemic is having on certain sectors, stakeholders, and therapy areas, is valuable. We can all agree that these are unprecedented and challenging times for the entire healthcare industry.
0 kommentar(er)
